Toremifene Citrate

Adrenal cortex is the outer layer of the gland involved in production of lifesaving hormones such as mineralocorticoids and glucocorticoids (aldosterone and cortisol) required for metabolism and stress management. Adrenal glands are located on the top of the kidneys. Adrenal cortical carcinoma is the cancer of adrenal cortex. There are two types of tumor associated with adrenal cortex, such as functioning tumor and non-functioning tumor. Functioning tumor is responsible for increase in the production of adrenal hormones, whereas, non-functioning tumor does not affect hormonal production. Adrenal cortical carcinoma is generally a secondary type of cancer. It occurs when another form of cancer spreads into the adrenal glands. Request Brochure of Report - Increasing incidence of adrenal cortical carcinoma due to spread of other form of cancer, advancement in imaging technologies to identify adrenal cortical tumors specifically, growing healthcare expenditure, and rising number of cancer treatment centers across the world are some of the dominating factors expected to fuel the growth of the global adrenal cortical carcinoma diagnosis and treatment market during the forecast period. For instance, according to the Journal of Clinical Endocrinology & Metabolism, adrenal cortical carcinoma is a rare and highly aggressive malignancy. The incidence rate for adrenal cortical carcinoma is 0.7–2.0 cases per million people. The disease is more common in women. It is generally diagnosed in the age group of 40 and 50 years. However, high incidence of adrenal cortical carcinoma is recorded among children in Brazil due to the high prevalence of a specific TP53 germline mutation in them. Request for Custom Research - The global adrenal cortical carcinoma diagnosis and treatment market can be segmented based on type of test, type of therapy, end-user, and region. In terms of type of test used for the diagnosis of adrenal cortical carcinoma, the market can be divided into magnetic resonance imaging (MRI), computed tomography (CT) scan, positron emission tomography (PET) scan, and biopsy. In terms of type of therapy, the adrenal cortical carcinoma diagnosis and treatment market can be categorized into surgery, chemotherapy, other drug therapy, radiation therapy, and biologic therapy. The surgery therapy segment can be further categorized into laparoscopic surgeries and open surgeries. The chemotherapy segment can be classified based on the type of drug used for the treatment into mitotane and the combination therapy of cisplatin, doxorubicin (adriamycin), and etoposide (VP-16) plus mitotane. The other drug therapy segment involves treatment of hormonal effects caused by the tumor. Drugs included in this type of therapy are spironolactone, mifepristone, tamoxifen, toremifene, etc. The radiation therapy segment can be bifurcated into external beam radiation therapy and brachytherapy. In terms of end-user, the adrenal cortical carcinoma diagnosis and treatment market can be segmented into hospitals, specialty cancer clinics, diagnostic centers, and others. Pre Book Adrenal Cortical Carcinoma Diagnosis and Treatment Market Report at - Based on geography, the global adrenal cortical carcinoma diagnosis and treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the adrenal cortical carcinoma diagnosis and treatment market owing to high per capita disposable income and increasing incidence of the adrenal cortical carcinoma in the region. For instance, according to the American Cancer Society, adrenal tumors (most of which are benign adenomas) are found in 1 in every 10 people who undergo tests such as CT scan or MRI of the adrenal gland. Europe is expected to be the second leading market for semen analysis due to high awareness about early diagnosis and treatment of the disease, favorable reimbursement facilities, and increasing healthcare expenditure in the region. Asia Pacific can be considered as an emerging market for the diagnosis and treatment of adrenal cortical carcinoma. Key players operating in the global adrenal cortical carcinoma diagnosis and treatment market include HRA Pharma, ER Squibb & Sons LLC, Bristol-Myers Squibb Company, GE healthcare, WG Critical Care, LLC, David Bull Laboratories (Pty) Ltd., Mylan Pharmaceuticals, Fresenius Kabi, Pfizer, SINOVISION Technologies(Beijing) Co., Ltd., Hitachi Medical Systems, NeuroLogica Corp., and Digirad Corporation. More Trending Reports by Transparency Market Research: Smart Hospitals Market: The high prevalence of active COVID-19 (coronavirus) cases in the U.S., India, Brazil, and Russia has triggered innovations in humanoid robots. Stakeholders in the smart hospitals market are taking cues from Beijing-based robotics company CloudMinds, which is providing humanoid robots in hospitals to free up human medical staff and limit the possibility of virus spread. Nucleic Acid Extraction Instruments & Reagents Market: Food security and global health face a constant threat from various existing and new plant and human diseases that are primarily caused by fungi, viruses, and different types of pathogens. Over the past few decades, the outbreak of various diseases including swine flu, Ebola, SARS, MERS, and the most recent COVID-19 has led to considerable loss of human lives and hindered the growth of the economy in several regions. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website:

MEMPHIS, Tenn., Aug. 3 /PRNewswire-FirstCall/ -- GTx, Inc. , the Men's Health Biotech Company, announced today that company management will present at the Bank of America Specialty Pharmaceuticals Conference at 1:30 p.m. Eastern time on August 10 at the Southampton Inn in Southampton, NY. The presentation will be simultaneously webcast. The link for the live webcast is . The presentation will also be accessible from the GTx website at . An archived replay of the presentation will be available until August 25, 2006. About GTx GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx is developing ostarine, a selective androgen receptor modulator, or SARM, for muscle wasting and bone loss indications. Ostarine is currently being evaluated in a Phase II clinical trial in 120 elderly men and postmenopausal women. GTx expects to have data from the Phase II ostarine trial in the fourth quarter of 2006. GTx has licensed to Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, another of its SARMs, andarine, under a joint collaboration and license agreement. Forward-Looking Information is Subject to Risk and Uncertainty This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties. GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that (i) GTx will not be able to commercialize its product candidates if clinical trials do not demonstrate safety and efficacy in humans; (ii) GTx may not able to obtain required regulatory approvals to commercialize its product candidates; (iii) GTx's clinical trials may not be completed on schedule, or at all, or may otherwise be suspended or terminated; and (iv) GTx could utilize its available cash resources sooner than it currently expects and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product development programs or commercialization efforts. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx's quarterly report on form 10-Q filed with the U.S. Securities and Exchange Commission on May 5, 2006, contains a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. GTx, Inc. CONTACT: McDavid Stilwell of GTx, Inc., +1-901-237-9640 Web site: